Waratah Capital Advisors Ltd. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,340 shares of the company’s stock, valued at approximately $3,654,000.
A number of other institutional investors also recently modified their holdings of the business. Pearl River Capital LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $28,000. Osborn Williams & Donohoe LLC purchased a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $90,000. Sontag Advisory LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $79,000. Quantamental Technologies LLC purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $92,000. Finally, Hall Laurie J Trustee increased its stake in shares of IDEXX Laboratories by 25.0% during the 1st quarter. Hall Laurie J Trustee now owns 500 shares of the company’s stock worth $112,000 after purchasing an additional 100 shares in the last quarter. 87.46% of the stock is owned by institutional investors.
In related news, insider Michael Lane sold 971 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $208.00, for a total transaction of $201,968.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Rebecca M. Henderson sold 8,790 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the sale, the director now owns 27,486 shares in the company, valued at approximately $6,639,793.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,457 shares of company stock worth $15,530,423. 2.70% of the stock is owned by company insiders.
NASDAQ IDXX traded up $3.73 during mid-day trading on Thursday, reaching $253.28. 8,099 shares of the stock were exchanged, compared to its average volume of 515,041. IDEXX Laboratories, Inc. has a 1-year low of $176.11 and a 1-year high of $256.22. The firm has a market cap of $21.66 billion, a P/E ratio of 59.52 and a beta of 0.97. The company has a debt-to-equity ratio of 14.81, a quick ratio of 0.74 and a current ratio of 1.01.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.13. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The firm had revenue of $576.06 million for the quarter, compared to analyst estimates of $575.04 million. During the same quarter last year, the business earned $1.01 earnings per share. IDEXX Laboratories’s revenue was up 7.1% compared to the same quarter last year. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 4.82 EPS for the current year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.